SAN DIEGO, June 12, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today announced that
they have engaged in a preclinical agreement through the OncoSec
Technology Access Program (TAP) with Jounce Therapeutics, Inc.,
(NASDAQ:JNCE) Cambridge, MA, a
company focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient
enrichment.
Under the agreement, Jounce can utilize OncoSec's gene delivery
technology to evaluate in vivo efficacy in murine models of
intratumorally-delivered therapeutic candidates. The agreement
includes the GENESIS™ research generator and proprietary
applicators developed for research use.
"We are excited to provide a preclinical delivery solution to
Jounce for early-stage research purposes and expand the data set
from our delivery technologies through our Technology Access
Program," said Punit Dhillon, CEO
and President of OncoSec. "Through the establishment of these
programs, OncoSec benefits from extensive, multi-party
characterization and validation of our proprietary, state-of-the
art electroporation technologies. We are pleased to be working with
Jounce to help advance their preclinical programs with these
technologies."
"OncoSec has developed a unique delivery technology that will
enable us to rapidly assess potential candidates in preclinical
models," said Debbie Law, Jounce's
Chief Scientific Officer. "We are delighted to be working
with OncoSec and leveraging their technology to help us evaluate
our preclinical immunotherapy programs."
About OncoSec Research Technologies and Technology Access
Program:
The OncoSec GENESIS™ research generator was developed
specifically for gene electro-transfer. It features customizable
electroporation parameters for construct-specific optimization of
expression, and it is the only in vivo electroporation
device enabled with TRACE™ Technology (Tissue-Based, Real-Time
Adaptive Control Electroporation.)
TRACE™ technology incorporates an electrochemical tissue-sensing
control system to automatically adjust pulse width and treatment
duration in real time during the electroporation procedure. This
feature enables tissue- and therapeutic-specific delivery
optimization, maximizing uptake of the therapeutic while reducing
unnecessary cell ablation or damage. In research models, GENESIS™
with TRACE™ has yielded higher and more consistent in vivo
protein expression versus fixed-parameter electroporation, even in
heterogeneous tissues.
Potential advantages of GENESIS™ with TRACE™ for use in murine
models include robust and conformationally-native in vivo
expression of difficult proteins, including GPCRs and receptors
that function in multimeric form. Moreover, the consistent results
obtained with these technologies in heterogeneous tissues support
reliable intratumoral delivery of a wide variety of DNA-encodable
therapeutics across multiple syngeneic, xenograft, and PDX models.
Using these technologies, OncoSec has expressed more than fifty
proteins in vivo, including multimers and
structurally-complex fusion proteins, and no protein tested to date
has failed to successfully express.
The OncoSec Technology Access Program makes OncoSec's
electroporation technologies available to collaborators for
preclinical research. Devices are available for intratumoral,
intradermal, and intramuscular delivery. For more information,
please contact bd@oncosec.com.
For SEC reporting purposes, the agreement between OncoSec and
Jounce is non-material.
About OncoSec Medical Incorporated:
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed
to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase I and II clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable safety
profile and evidence of anti-tumor activity in the treatment of
various solid tumors as well as the potential to initiate a
systemic immune response. OncoSec's lead program, ImmunoPulse®
IL-12, is currently in clinical development for several
indications, including metastatic melanoma, and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and developing
new immune-targeting agents for use with the ImmunoPulse® platform.
For more information, please visit www.oncosec.com.
About Jounce Therapeutics, Inc.:
Jounce Therapeutics, Inc. is a clinical stage immunotherapy
company dedicated to transforming the treatment of cancer by
developing therapies that enable the immune system to attack tumors
and provide long‑lasting benefits to patients. Through the use of
its Translational Science Platform, Jounce first focuses on
specific cell types within tumors to prioritize targets, and then
identifies related biomarkers designed to match the right therapy
to the right patient. Jounce's lead product candidate, JTX-2011, is
a monoclonal antibody that binds to and activates ICOS and is
currently in a Phase 1/2 trial. For more information, please visit
http://jouncetx.com/.
OncoSec Medical Incorporated Forward Looking
Statements
To the extent statements contained in this press release are not
descriptions of historical facts regarding OncoSec Medical
Incorporated, they may be considered forward looking statements, as
described in the Private Securities Litigation Reform Act of 1995,
reflecting management's current beliefs and expectations. Forward
looking statements speak only as of the date they are made, and
they are subject to known and unknown risks, uncertainties, and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from those anticipated by such statements. You can
identify forward-looking statements by words such as "aim,"
"anticipate," "believe," "can," "could," "estimate," "expect,"
"focus," "forecast," "intend," "may," "plan," "potential,"
"predict," "project," "should," "will," "would," or the negative of
those terms, and similar expressions that convey uncertainty of
future events or outcomes. Forward looking statements contained in
this press release include, but are not limited to, statements
regarding: (i) the success and timing of our product development
activities and clinical trials; (ii) our ability to develop and
commercialize our product candidates; (iii) our plans to research,
discover, evaluate and develop additional potential product,
technology and business candidates and opportunities; (iv) our and
our partners' ability to develop, manufacture and commercialize our
product candidates and to improve the manufacturing process; (v)
the size and growth potential of the markets for our product
candidates, and our ability to serve those markets; (vi) the rate
and degree of acceptance of our product candidates; (vii) our
ability to attract and retain key scientific or management
personnel; (viii) the anticipated timing of clinical data
availability; (ix) the anticipated timing of commercial launch of
ImmunoPulse® IL-12; (x) our ability to meet our milestones; (xi)
our expectations regarding our ability to obtain and maintain
intellectual property protection; (xii) the level of our corporate
expenditures; (xiii) the assessment of our technology by potential
corporate partners; and, (xiv) the impact of capital market
conditions on our Company. Undue reliance should not be placed on
forward looking statements. Such statements are subject to factors,
risks and uncertainties, such as those described in our periodic
filings with the Securities and Exchange Commission, including
without limitation our Quarterly Reports on Form 10-Q, our annual
reports on Form 10-K and other filings. Various factors may cause
actual results to differ materially from those expressed or implied
by such forward looking statements. We undertake no obligation to
publicly update any forward-looking statements. OncoSec's
investigational drug and device products have not been approved or
cleared by the FDA.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-announces-technology-access-program-agreement-with-jounce-therapeutics-inc-300472140.html
SOURCE OncoSec Medical Incorporated